EMBARGOED FOR RELEASE: 3 P.M. (CT), MONDAY, SEPTEMBER 9, 2013
Media Advisory: To contact author Jason M. Glanz, Ph.D., call Amy Whited at 303-344-7518 or email Amy.L.Whited@kp.org.
JAMA Pediatrics Study Highlights
Undervaccination Appears Associated with Increased Risk of Whooping Cough
Undervaccination with the diptheria, tetanus toxoids and acelluar pertussis (DTaP) vaccine appears to be associated with an increased risk of pertussis (whooping cough) in children 3 to 36 months of age, according to a study by Jason M. Glanz, Ph.D., of the Institute for Health Research at Kaiser Permanente Colorado, Denver.
“Undervaccination is an increasing trend that potentially places children and their communities at an increased risk for serious infectious disease,” according to the study.
The study involved children born between 2004 and 2008 and cared for at eight managed care organizations. Each child with laboratory-confirmed pertussis (72 patients) was matched to four randomly selected control patients for a total of 288 controls.
Undervaccincation was defined as missing any of four scheduled doses of the DTaP vaccine. Of 72 case patients with pertussis, 34 (47.22 percent) were undervaccinated for DTaP vaccine by the date of pertussis diagnosis compared to 64 (22.2 percent) of the control patients. Children undervaccinated for three or four doses of DTaP vaccine were 18.56 and 28.38 times more likely, respectively, to have received a diagnosis of pertussis than children who were age-appropriately vaccinated, the study reports.
“Undervaccination with DTaP vaccine increases the risk of pertussis among children 3 to 36 months of age,” the study concludes.
(JAMA Pediatr. Published online September 9, 2013. doi:10.1001/jamapediatrics.2013.2353. Available pre-embargo to the media at http://media.jamanetwork.com.)
Editor’s Note: This study was funded through a subcontract with America’s Health Insurance Plances under a contract from the Centers for Disease Control and Prevention. Please see the articles for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
# # #
For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email email@example.com.